ORIGINAL RESEARCH
Published on 20 May 2026
An anoikis-related gene signature predicts prognosis and immunotherapy response, and identifies CCAR2 as a therapeutic target in triple-negative breast cancer
doi 10.3389/fimmu.2026.1808490
- 1,386 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Integrating Immunotherapy into the Clinical Management of Triple-Negative Breast Cancer (TNBC): Biomarkers, Strategies, and Real-World Perspectives
Integrating Immunotherapy into the Clinical Management of Triple-Negative Breast Cancer (TNBC): Biomarkers, Strategies, and Real-World Perspectives
1,161
Total downloads
7,694
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
REVIEW
Published on 22 Apr 2026
Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers
doi 10.3389/or.2026.1802090
- 2,493 views
- 1 citation
ORIGINAL RESEARCH
Published on 10 Apr 2026
Comprehensive analysis of prognostic characteristics based on T cell-mediated tumor killing related genes in triple negative breast cancer
doi 10.3389/fimmu.2026.1801004
- 1,403 views
SYSTEMATIC REVIEW
Accepted on 21 Jul 2026
Datopotamab deruxtecan in breast cancer treatment: a systematic review of clinical efficacy and safety
- 211 views
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Other participating journals
Frontiers in Oncology
- 3.4 impact factor
- 6.6 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: